Skip to content

Netherlands Society of Gene and Cell Therapy

  • About
    • History
    • Mission
    • Board Members
    • Committees
    • Honorary Members
  • Education
    • Gene Therapy Basics
    • Cell Therapy Basics
    • Antisense Oligonucleotide Therapy Basics
    • Approved Therapies
  • Research
    • Gene and Cell Therapy in the Netherlands
      • Academic research groups
      • National initiatives
    • Greiner Award
    • NVGCT Outstanding Achievement Award
      • 2023 NVGCT Outstanding Achievement Award
      • 2022 NVGCT Outstanding Achievement Award
      • 2021 NVGCT Outstanding Achievement Award
      • 2020 NVGCT Outstanding Achievement Award
      • 2019 NVGCT Outstanding Achievement Award
    • Research News
    • Human Gene Therapy
    • Other Journals
    • Useful Links
    • Research Image Gallery
    • Research vacancies
  • Events
    • Webinars
    • Calendar
    • Annual Symposium
      • Annual Symposium 2025
    • Past events
      • Annual Symposium 2024
      • Annual Symposium 2023
      • Annual Symposium 2022
      • Annual Symposium 2020-2021
      • Spring Symposium 2019
      • Spring Symposium 2018
      • Patiënteninformatiedag Gentherapie
  • Get Involved
    • Become a Member
    • Become a sponsor
    • Contact
  • Patient Info (NL)
    • Dossier Gentherapie Stichting BWM
    • Patiënteninformatiedag Gentherapie
    • Veelgestelde vragen
  • Sign in

Category: Clinical development updates

Posted on 26/03/202108/07/2024

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

Posted on 23/03/202108/07/2024

Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy

Posted on 23/03/202108/07/2024

Genentech Provides Update on Tominersen Program in Manifest Huntington’s Disease: Dosing to stop in Phase III clinical study of tominersen

Posted on 19/03/202108/07/2024

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration

Posted on 19/03/202108/07/2024

Translate Bio Announces Results from Second Interim Data Analysis from Ongoing Phase 1/2 Clinical Trial of MRT5005 in Patients with Cystic Fibrosis (CF)

Posts navigation

Previous page Page 1 Page 2 Page 3 Next page

Upcoming events

Oct
29
Wed
all-day RNA Horizons 2025 Therapeutic Sy... @ NH Hotel Palermo
RNA Horizons 2025 Therapeutic Sy... @ NH Hotel Palermo
Oct 29 – Oct 31 all-day
RNA Horizons 2025 Therapeutic Symposium @ NH Hotel Palermo | Palermo | Sicilia | Italy
View Calendar
Add
  • Add to Timely Calendar
  • Add to Google
  • Add to Outlook
  • Add to Apple Calendar
  • Add to other calendar
  • Export to XML
  • LinkedIn
  • X
Privacy Statement Proudly powered by WordPress